FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to treatment of proliferative disease especially that one associated with a solid tumour. That is ensured by introduction of an effective amount of epothilone B of formula I 
wherein residual A represents O, R stands for hydrogen or methyl, and Z means O. The patient is exposed to ionising radiation additionally, simultaneously or consistently in any order.
EFFECT: choice of a specific epothilone derivative combined with radiation provides synergetic effect on suppression of tumour tissue.
8 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATIONS INCLUDING EPOTHILONES, AND THEIR PHARMACEUTICAL APPLICATION | 2002 |
|
RU2375058C2 |
| SYNERGIC METHODS AND COMPOSITIONS FOR CANCER TREATMENT | 2001 |
|
RU2264217C2 |
| COMBINATIONS INCLUDING EPOTHILONES AND THEIR PHARMACEUTICAL APPLICATION | 2003 |
|
RU2379032C9 |
| COMBINATIONS CONTAINING EPOTHILONES AND ANTIMETABOLITES | 2003 |
|
RU2346686C2 |
| COMBINATIONS CONTAINING EPOTHILONES AND PROTEIN KINASE INHIBITORS AND PHARMACEUTICAL APPLICATION THEREOF | 2005 |
|
RU2423980C2 |
| COMBINATION CONTAINING IRON COMPLEX AND ANTINEOPLASTIC AGENT, AND USE THEREOF | 2007 |
|
RU2469721C2 |
| COMBINATIONS CONTAINING ANTIDIARRHEAL AGENT AND EPOTHYLON OR EPOTHYLON DERIVATIVES | 2002 |
|
RU2330661C2 |
| COMBINATION OF HISTONE DEACETYLASE INHIBITORS AND RADIATION | 2006 |
|
RU2436572C2 |
| APPLYING EPOTILONES FOR CANCER TREATMENT | 1999 |
|
RU2242229C2 |
| COMPOSITIONS CONTAINING SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | 2002 |
|
RU2333754C2 |
